Sirpiglenastat
General
Type : Pro-Drug || Drug || Peptide
Chemical_Nomenclature : propan-2-yl (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate
Canonical SMILES : CC(C)OC(=O)C(CCC(=O)C=[N+]=[N-])NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C
InChI : InChI=1S\/C22H27N5O5\/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18\/h4-7,11-13,19-20,24H,8-10H2,1-3H3,(H,26,28)(H,27,30)\/t19-,20-\/m0\/s1
InChIKey : LQNMCWOJACNQQM-PMACEKPBSA-N
Other name(s) : CHEMBL4650367, SCHEMBL20465436, (-)-sirpiglenastat, DRP-104, Ac-Trp-Glu(Unk)-OiPr
Target
Families : Carb_B_Chordata
References (2)
| Title : Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug - Rais_2022_Sci.Adv_8_eabq5925 |
| Author(s) : Rais R , Lemberg KM , Tenora L , Arwood ML , Pal A , Alt J , Wu Y , Lam J , Aguilar JMH , Zhao L , Peters DE , Tallon C , Pandey R , Thomas AG , Dash RP , Seiwert T , Majer P , Leone RD , Powell JD , Slusher BS |
| Ref : Sci Adv , 8 :eabq5925 , 2022 |
| Abstract : Rais_2022_Sci.Adv_8_eabq5925 |
| ESTHER : Rais_2022_Sci.Adv_8_eabq5925 |
| PubMedSearch : Rais_2022_Sci.Adv_8_eabq5925 |
| PubMedID: 36383674 |
| Title : Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems - Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| Author(s) : Yokoyama Y , Estok TM , Wild R |
| Ref : Mol Cancer Ther , 21 :1561 , 2022 |
| Abstract : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| ESTHER : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| PubMedSearch : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| PubMedID: 35930753 |